京都大学大学院医学研究科 血液・腫瘍内科学

研究

ホーム ＞ 研究 ＞ 臨床研究グループ

臨床研究グループ

2022年の業績

  • Morimoto S, Kondo T, Taya T, Matsuo H, Teramoto Y, Mizumoto C, Kanda J, Yamashita K, Takaori-Kondo A. Successful allogeneic bone marrow transplantation in a case of variant acute promyelocytic leukemia with ZBTB16-RARA.Ann Hematol101(5): 1129-1132, 2022.
  • Iemura T, Arai Y, Kitawaki T, Kanda J, Kondo T, Ueda Y, Mori T,Imada K, Yonezawa A, Yago K, Anzai N ,Kotani S,Nohgawa M, Kitano T, Itoh M, Arima N ,Moriguchi T, Watanabe M, Tsuji M,Yamashita K , Takaori-Kondo A , the Kyoto Stem Cell Transplantation Group (KSCTG). Coexistence of HLA and KIR ligand mismatches as a risk factor for viral infection early after cord blood transplantation. Bone Marrow Transplant. 57(5): 781-789, 2022.
  • Hamada R, Kondo T, Harada K, Murao M, Miyasaka J, Yoshida M, Yonezawa H, Nankaku M, Arai Y, Kanda J, Takaori-Kondo A, Ikeguchi R, Matsuda S. Evaluation of indices for predicting recovery of exercise tolerance in patients surviving allogenic hematopoietic stem cell transplantation. Support Care Cancer 30(5): 4027-4034, 2022.
  • Iwasaki M, Kanda J, Tanaka H, Shindo T, Sato T, Doki N, Fukuda T, Ozawa Y, Eto T, Uchida N, Katayama Y, Kataoka K, Ara T, Ota S, Onizuka M, Kanda Y, Ichinohe T, Atsuta Y, Morishima S. Impact of HLA Epitope Matching on Outcomes After Unrelated Bone Marrow Transplantation.Frontiers in Immunology, 13: 811733, 2022.
  • Itonaga H, Kida M, Doki N, Uchida N, Ozawa Y, Fukuda T, Ueda Y, Kataoka K, Katayama Y, Ota S, Matsuoka KI, Kondo T, Eto T, Kanda J, Ichinohe T, Atsuta Y, Miyazaki Y, Ishiyama K. Outcome of therapy-related myelodysplastic syndrome and oligoblastic acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation: A propensity score matched analysis.Hematol Oncol 40(4): 752-762, 2022. .
  • Tashiro Y, Kanda J, Iemura T, Kondo T, Yamashita K, Sunada M, Horie A, Takaori-Kondo A. Feasibility of ovarian stimulation for fertility preservation during and after blinatumomab treatment for Ph-negative B-cell acute lymphoblastic leukemia.Int J Hematol 116(3): 453-458, 2022.
  • Fujita J, Taniguchi M, Hashizume C, Ueda Y, Sakai S, Kondo T, Hashimoto-Nishimura M, Hanada K, Kosaka T, Okazaki T. Nuclear ceramide is associated with ATM activation in the neocarzinostatin-induced apoptosis of lymphoblastoid cells. Mol Pharmacol 101(5): 322-333, 2022.
  • Suminaga Y, Chigusa Y , Kondo T, Okamoto H, Kawamura Y, Taki M, Mandai M, and Mogami H. Aplastic anemia treated with eltrombopag during pregnancy. Case Rep Obstet Gynecol2022: 5889427, 2022.
  • Muranushi H, Kanda J, Kobayashi M, Maeda T, Kitano T, Tsuji M, Ueda Y, Ishikawa T, Nohgawa M, Watanabe M, Imada K, Moriguchi T, Itoh M, Ohno H, Yonezawa A, Hirata H, Arima N, Asagoe K, Anzai N, Nagata K, Yasuno S, Kuwabara Y, Kitao H, Kim I, Kawagishi K, Ueshima K, Tominari S, Nakayama T, Yamashita K, Takaori-Kondo A. Bortezomib-cyclophosphamide-dexamethasone induction/consolidation and bortezomib maintenance for transplant-eligible newly diagnosed multiple myeloma: phase 2 multicenter trial. Hematology. 27(1):239-248, 2022.
  • Wada F, Watanabe M, Konuma T, Okabe M, Kobayashi S, Uchida N, Ikegame K, Tanaka M, Sugio Y, Mukae J, Onizuka M, Kawakita T, Kuriyama T, Takahashi S, Fukuda T, Nakano N, Sawa M, Kimura T, Ichinohe T, Atsuta Y, Kanda J ; Donor/Source Working Group of the Japan Society for Hematopoietic Cell Transplantation. HLA 1-3 antigen-mismatched related peripheral blood stem cells transplantation using low-dose antithymocyte globulin versus unrelated cord blood transplantation. Am J Hematol. 97:311-321, 2022.
  • Ishii A, Jo T, Arai Y, Oshima S, Kanda J, Kitawaki T, Matsui K, Niwa N, Nakagawa Y, Takaori-Kondo A, Nagao M. Development of a quantitative prediction model for peripheral blood stem cell collection yield in the plerixafor era.Cytotherapy . 24: 49-58, 2022.
  • Kanda J , Hayashi H, Ruggeri A, Kimura F, Volt F, Takahashi S, Kako S, Tozatto-Maio K, Yanada M, Sanz G, Uchida N, Angelucci E, Kato S, Mohty M, Forcade E, Tanaka M, Sierra J, Ohta T, Saccardi R, Fukuda T, Ichinohe T, Kimura T, Rocha V, Okamoto S, Nagler A, Atsuta Y, Gluckman E. The impact of GVHD on outcomes after adult single cord blood transplantation in European and Japanese populations. Bone Marrow Transplant. 57: 57-64, 2022.
  • Kobayashi S, Kanda Y, Konuma T, Inamoto Y, Matsumoto K, Uchida N, Ikegame K, Miyamoto T, Doki N, Nakamae H, Katayama Y, Takahashi S, Shiratori S, Saito S, Kawakita T, Kanda J, Fukuda T, Atsuta Y, Kimura F. Outcomes of third allogeneic hematopoietic stem cell transplantation in relapsed/refractory acute leukemia after a second transplantation. Bone Marrow Transplant. 57: 43-50, 2022.
  • Kato K, Makita S, Goto H, Kanda J, Fujii N, Shimada K, Akashi K, Izutsu K, Teshima T, Fukuda N, Sumitani T, Sumi H, Shimizu S, Kakurai Y, Yoshikawa K, Tobinai K, Usui N, Hatake K. Phase 2 study of axicabtagene ciloleucel in Japanese patients with relapsed or refractory large B-cell lymphoma. Int J Clin Oncol. 227: 213-223, 2022.
  • Yokoyama H, Hirayama M, Takahashi Y, Uchida N, Tanaka M, Onizuka M, Ozawa Y, Onai D, Katsuoka Y, Wake A, Sawa M, Kobayashi H, Maruyama Y, Ozeki K, Kimura T, Kanda J, Fukuda T, Atsuta Y, Terakura S, Morishima S. Altered effect of killer immunoglobulin-like receptor-ligand mismatch by graft versus host disease prophylaxis in cord blood transplantation. Bone Marrow Transplant. 56: 3059-3067, 2022.
  • Kurosawa S, Mizuno S, Arai Y, Masuko M, Kanda J, Kohno K, Onai D, Fukuda T, Ozawa Y, Katayama Y, Tanaka M, Ikegame K, Uchida N, Eto T, Ota S, Tanaka J, Ichinohe T, Atsuta Y, Yanada M. Syngeneic hematopoietic stem cell transplantation for acute myeloid leukemia: a propensity score-matched analysis.Blood Cancer J . 11: 159, 2022.
  • Wakita S, Sakaguchi M, Oh I, Kako S, Toya T, Najima Y, Doki N, Kanda J, Kuroda J, Mori S, Satake A, Usuki K, Ueki T, Uoshima N, Kobayashi Y, Kawata E, Tajika K, Nagao Y, Shono K, Shibusawa M, Tadokoro J, Kayamori K, Hagihara M, Uchiyama H, Uchida N, Kubota Y, Kimura S, Nagoshi H, Ichinohe T, Kurosawa S, Motomura S, Hashimoto A, Muto H, Sato E, Ogata M, Mitsuhashi K, Ando J, Marumo A, Omori I, Fujiwara Y, Terada K, Yui S, Arai K, Kitano T, Miyata M, Kurosawa A, Mizoguchi A, Komatsu N, Fukuda T, Ohashi K, Kanda Y, Inokuchi K, Yamaguchi H. Prognostic impact of CEBPA bZIP domain mutation in acute myeloid leukemia. Blood Adv. 6: 238-247, 2022.
  • Hiramoto N, Yamazaki H, Nakamura Y, Uchida N, Murata M, Kondo T, Yoshioka S, Eto T, Nishikawa A, Kimura T, Ichinohe T, Atsuta Y, Onishi Y, Suzuki R, Mori T on behalf of on behalf of the Adult Aplastic Anemia Working Group of the Japanese Society for Hematopoietic Cell Transplantation. Total body irradiation‑containing conditioning regimens without antithymocyte globulin in adults with aplastic anemia undergoing umbilical cord blood transplantation. Ann Hematol. 101(1): 165-175, 2022.
  • Hamada R, Oshima Y, Sato S, Yoshioka Y, Nankaku M, Kondo T, F. Chen-Yoshikawa T, Ikeguchi R, Nakajima D, Date H, Matsuda S. Changes in the health-related quality of life and social reintegration status after lung transplantation following hematopoietic stem cell transplantation. Support Care Cancer.30(2): 1831-1839, 2022.
  • Imahashi N, Terakura S, Kondo E, Kato K, Kim SW, Shinohara A, Watanabe M, Fukuda T, Uchida N, Kobayashi H, Ishikawa J,Kataoka K, Shiratori S, Ikeda T, Matsuoka KI, Yoshida S, Kondo T, Kimura T, Onizuka M, Ichinohe T, Atsuta Y, and Kanda J. Impact of donor types on reduced-intensity conditioning allogeneic stem cell transplant for mature lymphoid malignancies. Bone Marrow Transplant. 57(2): 243-251, 2022.
  • Kawajiri A, Kawase T, Tanaka H, Fukuda T, Mukae J, Ozawa Y, Eto T, Uchida U, Mori T, Ashida T, Kondo T, Onizuka M, Ichinohe T, Atsuta Y, Morishima S, and Kanda J, on behalf of the HLA Working Group of the Japan Society for Hematopoietic Cell Transplantation. Human leukocyte antigen (HLA) haplotype matching in unrelated single HLA allele mismatch bone marrow transplantation. Bone Marrow Transplant. 57(3): 407-415, 2022.
  • Hiramoto N, Yamazaki H, Nakamura Y, Uchida N, Murata M, Kondo T, Yoshioka S, Eto T, Nishikawa A, Kimura T, Ichinohe T, Atsuta Y, Onishi Y, Suzuki R, Mori T on behalf of on behalf of the Adult Aplastic Anemia Working Group of the Japanese Society for Hematopoietic Cell Transplantation. Total body irradiation‑containing conditioning regimens without antithymocyte globulin in adults with aplastic anemia undergoing umbilical cord blood transplantation.Ann Hematol . 101(1): 165-175, 2022.
  • Hamada R, Asano T, Murao M, Miyasaka J, Matsushita M, Kajimoto T, Otagaki A, Nankaku M, Arai Y, Kanda J, Kondo T, Takaori-Kondo A, Ikeguchi R, Matsuda S. Intramuscular Adipose Tissue Content Predicts Patient Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation. Transplant Cell Ther. 28: 602.e1-7, 2022.
  • Wada F, Jo T, Arai Y, Kitawaki T, Mizumoto C, Kanda J, Nishikori M, Yamashita K, Nagao M, Takaori-Kondo A. T-cell counts in peripheral blood at leukapheresis predict responses to subsequent CAR-T cell therapy.Sci Rep . 12(1): 18696, 2022.
  • Nishiwaki S, Akahoshi Y, Morita-Fujita M, Shimizu H, Uchida N, Ozawa Y, Fukuda T, Tanaka M, Ikegame K, Ota S, Katayama Y, Takahashi S, Kawakita T, Ara T, Onizuka M, Kimura T, Tanaka J, Atsuta Y, Arai Y. Improvements in allogeneic hematopoietic cell transplantation outcomes for adults with ALL over the past 3 decades. Blood Adv. 6(15): 4558-4569, 2022.
  • Morita-Fujita M, Arai Y, Kondo T, Harada K, Uchida N, Toya T, Ozawa Y, Fukuda T, Ota S, Onizuka M, Kanda Y, Maruyama Y, Takada S, Kawakita T, Ara T, Ichinohe T, Kimura T, Atsuta Y, Kako S. Adult patients with Ph+ ALL benefit from conditioning regimen of medium-dose VP16 plus CY/TBI.Hematol Oncol . 40(5): 1041-1055, 2022.
  • Jo T, Arai Y, Kondo T, Mizuno S, Hirabayashi S, Inamoto Y, Doki N, Fukuda T, Ozawa Y, Katayama Y, Kanda Y, Fukushima K, Matsuoka KI, Takada S, Sawa M, Ashida T, Onizuka M, Ichinohe T, Atsuta Y, Kanda J, Yanada M. Advantages of peripheral-blood stem cells from unrelated donors versus bone marrow transplants on outcomes of adult AML patients.Cytotherapy . 24(10): 1013-1025, 2022.
  • Yamasaki-Morita M, Arai Y, Ishihara T, Onishi T, Shimo H, Nakanishi K, Nishiyama Y, Jo T, Hiramatsu H, Mitsuyoshi T, Mizumoto C, Kanda J, Nishikori M, Kitawaki T, Nogami K, Takaori-Kondo A, Nagao M, Adachi S. Relative hypercoagulation induced by suppressed fibrinolysis after tisagenlecleucel infusion in malignant lymphoma.Blood Adv . 6(14): 4216-4223, 2022.
  • Arai Y, Chi S, Minami Y, Yanada M. FLT3-targeted treatment for acute myeloid leukemia.Int J Hematol . 116(3): 351-363, 2022.
  • Jo T, Yoshihara S, Hada A, Arai Y, Kitawaki T, Ikemoto J, Onomoto H, Sugiyama H, Yoshihara K, Obi N, Matsui K, Niwa N, Nakagawa Y, Kanda J, Kondo T, Saida S, Kato I, Hiramatsu H, Adachi S, Takita J, Takaori-Kondo A, Nagao M. A clinically applicable prediction model to improve T-cell collection in CAR-T cell therapy.Transplant Cell Ther . 28(7): 365.e1-365.e7, 2022.
  • Harada K, Morita-Fujita M, Fukuda T, Ozawa Y, Doki N, Toyosaki M, Maruyama Y, Kanda Y, Ashida T, Eto T, Takada S, Uchida N, Ichinohe T, Kanda J, Onizuka M, Atsuta Y, Kako S, Arai Y. Overcoming minimal residual disease using intensified conditioning with medium-dose etoposide, cyclophosphamide and total body irradiation in allogeneic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia in adults. Cytotherapy. 24(9): 954-961, 2022.
  • Oka T, Kondo T, Mizumoto C, Kanda J, Yamashita K, Takaori-Kondo A. [Durable remission following donor lymphocyte infusion for post-transplant relapse of acute myeloid leukemia developing from secondary myelofibrosis].Rinsho Ketsueki . 63(12): 1639-1642, 2022.